Taj Group India
  Quality Medicines Diseases Newsroom Feed back Contactus
IT Services
Home >> 
Wipro Infotech
Taj Products
Therapeutic Index
Allopathic Products
Ayurveic & Herbals
Product Index(M.R.P.)
Down Menu

Taj Brands

Therapeutic Index


Each tablet contains :



Atorvastatin………......................................... 10 mg

Atorvastatin………......................................... 20 mg


Indications :

Lipirol is a prescription drug. It is used in patients with multiple risk factors for heart disease  such as family history, high blood pressure, age ,low HDL or smoking to reduce the risk of heart attack and stroke.  Lipirol is also used in patients with type 2 diabetes and at least one other risk factor for heart disease such as high blood  pressure, smoking or complications of diabetes, including eye disease and protein in urine, to reduce the risk of heart attack and stroke.



Atorvastatin (Lipitor) is a selective, competitive inhibitor of HMG

CoA reductase, the rate-limiting  enzyme that converts 3-hydroxy

3-methylglutaryl-coenzyme A to mevalonate, a precursor of

sterols, including cholesterol. Cholesterol and triglycerides

circulate in the bloodstream as party of lipoprotein complexes.

With ultracentrifugation, these complexes separate into HDL

(high-density lipoprotein), IDL (intermediate-density lipoprotein),

LDL (low-density lipoprotein), and VLDL (very-low-density

lipoprotein) fractions.

Triglycerides (TG) and cholesterol in the liver are incorporated into

VLDL and released into the plasma for delivery to peripheral

tissues. LDL is formed from VLDL and is catabolized primarily

through the high-affinity LDL receptor. Clinical and pathologic

studies wshow that elevated plasma levels of total cholestero

(total-C), LDL-cholesterol (LDL-C), and apolipoprotein B (apo B)

promote human atherosclerosis and are risk factors for

developing cardiovascular disease, while increased levels of

HDL-C are associated with a decreased cardiovascular risk.

In animal models, Atorvastatin (Lipitor) lowers plasma cholesterol

and lipoprotein levels by inhibiting     HMG-CoA reductase and

cholesterol synthesis in the liver and by increasing the number of

hepatic LDL receptors on the cell-surface to enhance uptake and

catabolism of LDL; Atorvastatin (Lipitor) also reduces LDL

production and the number of LDL particles. Atorvastatin (Lipitor)

reduces LDL-C in some patients with homozygous familial

hypercholesterolemia (FH), a population that rarely responds to

other lipid-lowering medication.

A variety of clinical studies have demonstrated that elevated levels

of total-C, LDL-C, and apo B (a membrane complex for LDL-C)

promote human atherosclerosis. Similarly, decreased levels of

HDL-C (and its transport complex, apo A) are associated with the

development of atherosclerosis. Epidemiologic investigations

have established that cardiovascular morbidity and mortality vary

directly with the level of total-C and LDL-C, and inversely with the

level of HDL-C. Although frequently found in association with low

HDL-C, elevated plasma TG has not been established as an

independent risk factor for coronary heart disease. The

independent effect of of raising HDL-C or lowering TG on the risk

fro coronary and cardiovascular morbidity and mortality has not

been established.

Atorvastatin (Lipitor) reduces total-C, LDL-C, and apo B in patients

with homozygous and heterozygous FH, nonfamilial forms of

hypercholesterolemia, and mixed dyslipidemia. Atorvastatin

(Lipitor) also reduces VLDL-C and TG and produces variable

increases in HDL-C and apolipoprotein A-1. The effect of

Atorvastatin (Lipitor) on cardiovascular morbidity and mortality has

not been determined.

Like LDL, cholesterol-enriched triglyceride-rich lipoproteins,

including VLDL, intermediate density lipoprotein (IDL), and

remnants, can also promote atherosclerosis. Elevated plasma

triglycerides are frequently found in a triad with low HDL-C levels

and small LDL particles, as well as in association with non-lipid

metabolic risk factors for coronary heart disease. As such, total

plasma TG has not consistently been shown to be an

independent risk factor for CHD. Furthermore, the independent

effect of raising HDL or lowering TG on the risk of coronary and

cardiovascular morbidity and mortality has not been determined.

Dosage: As per the physician’s advice.

Presentations:                   MRP       Retailer   Stockist
                10 tablets            25.20       20.16         18.14
                10 tablets            49.50       39.60         35.64






Product Downloads:-







Structural Formula


Taj Values


Copyright © Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap